IL152934A0 - Methods and compositions for treating hepatitis c virus - Google Patents
Methods and compositions for treating hepatitis c virusInfo
- Publication number
- IL152934A0 IL152934A0 IL15293401A IL15293401A IL152934A0 IL 152934 A0 IL152934 A0 IL 152934A0 IL 15293401 A IL15293401 A IL 15293401A IL 15293401 A IL15293401 A IL 15293401A IL 152934 A0 IL152934 A0 IL 152934A0
- Authority
- IL
- Israel
- Prior art keywords
- virus
- compositions
- methods
- treating hepatitis
- hepatitis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03C—PHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
- G03C1/00—Photosensitive materials
- G03C1/005—Silver halide emulsions; Preparation thereof; Physical treatment thereof; Incorporation of additives therein
- G03C1/0051—Tabular grain emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20658500P | 2000-05-23 | 2000-05-23 | |
PCT/US2001/016671 WO2001090121A2 (en) | 2000-05-23 | 2001-05-23 | Methods and compositions for treating hepatitis c virus |
Publications (1)
Publication Number | Publication Date |
---|---|
IL152934A0 true IL152934A0 (en) | 2003-06-24 |
Family
ID=22767031
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15293401A IL152934A0 (en) | 2000-05-23 | 2001-05-23 | Methods and compositions for treating hepatitis c virus |
IL152934A IL152934A (en) | 2000-05-23 | 2002-11-19 | Use of a nucleoside in the manufacture of a medicament for treating heapatitis c virus |
IL196301A IL196301A0 (en) | 2000-05-23 | 2008-12-31 | Medicament for the treatment of hapatitis c |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL152934A IL152934A (en) | 2000-05-23 | 2002-11-19 | Use of a nucleoside in the manufacture of a medicament for treating heapatitis c virus |
IL196301A IL196301A0 (en) | 2000-05-23 | 2008-12-31 | Medicament for the treatment of hapatitis c |
Country Status (27)
Families Citing this family (316)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2415776T3 (en) * | 1998-08-10 | 2016-07-04 | Novartis Ag | Beta-L-2'-deoxy nucleosides for the treatment of Hepatitis B |
US6444652B1 (en) | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
US20020056123A1 (en) * | 2000-03-09 | 2002-05-09 | Gad Liwerant | Sharing a streaming video |
JP2003532643A (ja) | 2000-04-13 | 2003-11-05 | フアーマセツト・リミテツド | 肝炎ウイルス感染症を治療するための3’−または2’−ヒドロキシメチル置換ヌクレオシド誘導体 |
MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
KR20030036189A (ko) * | 2000-05-26 | 2003-05-09 | 이데닉스(케이만)리미티드 | 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물 |
US20030008841A1 (en) * | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
PT1411954E (pt) | 2000-10-18 | 2011-03-16 | Pharmasset Inc | Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal |
CN1267446C (zh) * | 2001-01-22 | 2006-08-02 | 默克公司 | 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物 |
US8481712B2 (en) | 2001-01-22 | 2013-07-09 | Merck Sharp & Dohme Corp. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US7105499B2 (en) * | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
GB0114286D0 (en) * | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
US20050009775A1 (en) * | 2001-06-21 | 2005-01-13 | Howes Peter David | Nucleoside compounds in hcv |
EP1478322A4 (en) | 2001-06-22 | 2007-08-08 | Pharmasset Ltd | Beta 2'-OR 3'-HALONUCLEOSIDE |
AU2002353164A1 (en) * | 2001-12-17 | 2003-06-30 | Ribapharm Inc. | Unusual nucleoside libraries, compounds, and preferred uses as antiviral and anticancer agents |
WO2003062256A1 (en) * | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
EP1572705A2 (en) * | 2002-01-17 | 2005-09-14 | Ribapharm, Inc. | Sugar modified nucleosides as viral replication inhibitors |
US7217815B2 (en) | 2002-01-17 | 2007-05-15 | Valeant Pharmaceuticals North America | 2-beta -modified-6-substituted adenosine analogs and their use as antiviral agents |
AU2003209045B2 (en) * | 2002-02-13 | 2006-12-14 | Isis Pharmaceuticals, Inc. | Methods of inhibiting orthopoxvirus replication with nucleoside compounds |
US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
KR20050006221A (ko) * | 2002-05-06 | 2005-01-15 | 제네랩스 테크놀로지스, 인코포레이티드 | C형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체 |
CA2488534A1 (en) * | 2002-06-21 | 2003-12-31 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
US20060234962A1 (en) * | 2002-06-27 | 2006-10-19 | Olsen David B | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
RS114104A (en) | 2002-06-28 | 2007-02-05 | Idenix (Cayman) Limited, | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |
CN101172993A (zh) * | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2′-c-甲基-3′-o-l-缬氨酸酯核糖呋喃基胞苷 |
DE14169110T1 (de) * | 2002-06-28 | 2022-05-12 | Centre National De La Recherche Scientifique -Cnrs- | Modifizierte 2'- und 3'-Nukleosid-Prodrugs zur Behandlung von Flaviridae-Infektionen |
AU2003248748A1 (en) * | 2002-06-28 | 2004-01-19 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
US20060264389A1 (en) * | 2002-07-16 | 2006-11-23 | Balkrishen Bhat | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
AU2003256619A1 (en) * | 2002-07-24 | 2004-02-09 | Isis Pharmaceuticals, Inc. | Pyrrolopyrimidine thionucleoside analogs as antivirals |
WO2004011647A1 (en) | 2002-07-26 | 2004-02-05 | Chiron Corporation | Modified small interfering rna molecules and methods of use |
SG174624A1 (en) * | 2002-08-01 | 2011-10-28 | Pharmasset Inc | Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections |
US20040067877A1 (en) | 2002-08-01 | 2004-04-08 | Schinazi Raymond F. | 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections |
MXPA05003400A (es) * | 2002-09-30 | 2005-06-22 | Genelabs Tech Inc | Derivados de nucleosidos para tratar la infeccion por el virus de la hepatitis c. |
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
US7148349B2 (en) * | 2002-10-31 | 2006-12-12 | Metabasis Therapeutics, Inc. | Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs |
US7902203B2 (en) | 2002-11-01 | 2011-03-08 | Abbott Laboratories, Inc. | Anti-infective agents |
KR20050088079A (ko) | 2002-11-15 | 2005-09-01 | 이데닉스 (케이만) 리미티드 | 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이 |
TWI332507B (en) | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
US7034167B2 (en) | 2002-12-06 | 2006-04-25 | Merck & Co., Inc. | Process to ribofuranose sugar derivatives as intermediates to branched-chain nucleosides |
EP2319853B1 (en) * | 2002-12-12 | 2014-03-12 | IDENIX Pharmaceuticals, Inc. | Process for the production of 2'-branched nucleosides |
RU2005123395A (ru) * | 2002-12-23 | 2006-01-27 | Айденикс (Кайман) Лимитед (Ky) | Способ получения 3-нуклеозидных пролекарств |
US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
AR043006A1 (es) | 2003-02-12 | 2005-07-13 | Merck & Co Inc | Proceso para preparar ribonucleosidos ramificados |
WO2004084453A2 (en) * | 2003-03-20 | 2004-09-30 | Microbiologica Quimica E Farmaceutica Ltd. | METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES |
RU2005133093A (ru) * | 2003-03-28 | 2006-07-27 | Фармассет, Инк. (Us) | Соединения для лечения флавивирусных инфекций |
CA2523083C (en) | 2003-04-25 | 2014-07-08 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
US20040259934A1 (en) * | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
US7429572B2 (en) | 2003-05-30 | 2008-09-30 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
RU2375350C2 (ru) | 2003-06-04 | 2009-12-10 | Смитклайн Бичам Корпорейшн | Азотсодержащие производные гетероарила |
US7572581B2 (en) | 2003-06-30 | 2009-08-11 | Roche Molecular Systems, Inc. | 2′-terminator nucleotide-related methods and systems |
US7947817B2 (en) | 2003-06-30 | 2011-05-24 | Roche Molecular Systems, Inc. | Synthesis and compositions of 2'-terminator nucleotides |
US20050075309A1 (en) * | 2003-07-25 | 2005-04-07 | Richard Storer | Purine nucleoside analogues for treating Flaviviridae including hepatitis C |
TW200517381A (en) | 2003-08-01 | 2005-06-01 | Genelabs Tech Inc | Bicyclic heteroaryl derivatives |
WO2005018330A1 (en) * | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
CA2537114C (en) | 2003-08-27 | 2012-10-02 | Biota, Inc. | Tricyclic nucleosides or nucleotides as therapeutic agents |
ATE465742T1 (de) * | 2003-09-05 | 2010-05-15 | Anadys Pharmaceuticals Inc | Tlr7-liganden zur behandlung von hepatitis c |
AU2004274021B2 (en) * | 2003-09-18 | 2009-08-13 | Isis Pharmaceuticals, Inc. | 4'-thionucleosides and oligomeric compounds |
JP4704342B2 (ja) | 2003-09-22 | 2011-06-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎ウイルスに対し活性な大環状ペプチド |
EP1670448B1 (en) * | 2003-09-30 | 2007-11-21 | Tibotec Pharmaceuticals Ltd. | Hcv inhibiting sulfonamides |
CN103145715B (zh) | 2003-10-14 | 2016-08-03 | F·霍夫曼-罗须公司 | 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺 |
US7144868B2 (en) | 2003-10-27 | 2006-12-05 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
NZ546201A (en) | 2003-10-27 | 2009-05-31 | Genelabs Tech Inc | Nucleoside compounds for treating viral infections |
US7157434B2 (en) | 2003-10-27 | 2007-01-02 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
CA2543116A1 (en) | 2003-10-27 | 2005-05-19 | Genelabs Technologies, Inc. | Methods for preparing 7-(2'-substituted-.szlig.-d-ribofuranosyl)-4-(nr2r3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives |
US7202223B2 (en) | 2003-10-27 | 2007-04-10 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
GB0500020D0 (en) | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
JP4682155B2 (ja) | 2004-01-21 | 2011-05-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎ウイルスに対して活性な大環状ペプチド |
US20050182252A1 (en) * | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
ES2431314T3 (es) | 2004-02-20 | 2013-11-26 | Boehringer Ingelheim International Gmbh | Inhibidores de polimerasa vírica |
AU2005254057B2 (en) | 2004-06-15 | 2011-02-17 | Isis Pharmaceuticals, Inc. | C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase |
BRPI0512360A (pt) * | 2004-06-23 | 2008-03-11 | Idenix Cayman Ltd | derivados de 5-aza-7-deazapurina para o tratamento de flaviviridae |
CA2571079A1 (en) * | 2004-06-24 | 2006-02-02 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
US7745125B2 (en) | 2004-06-28 | 2010-06-29 | Roche Molecular Systems, Inc. | 2′-terminator related pyrophosphorolysis activated polymerization |
CN101023094B (zh) * | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
PT1778251E (pt) * | 2004-07-27 | 2011-06-29 | Gilead Sciences Inc | Análogos de fosfonato de compostos inibidores de vih |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
WO2006031725A2 (en) | 2004-09-14 | 2006-03-23 | Pharmasset, Inc. | Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
WO2006121468A1 (en) | 2004-11-22 | 2006-11-16 | Genelabs Technologies, Inc. | 5-nitro-nucleoside compounds for treating viral infections |
WO2006093801A1 (en) | 2005-02-25 | 2006-09-08 | Abbott Laboratories | Thiadiazine derivatives useful as anti-infective agents |
WO2006093987A1 (en) | 2005-02-28 | 2006-09-08 | Genelabs Technologies, Inc. | Tricyclic-nucleoside compounds for treating viral infections |
US7524831B2 (en) | 2005-03-02 | 2009-04-28 | Schering Corporation | Treatments for Flaviviridae virus infection |
US8802840B2 (en) | 2005-03-08 | 2014-08-12 | Biota Scientific Management Pty Ltd. | Bicyclic nucleosides and nucleotides as therapeutic agents |
US20090156545A1 (en) * | 2005-04-01 | 2009-06-18 | Hostetler Karl Y | Substituted Phosphate Esters of Nucleoside Phosphonates |
CA2606195C (en) | 2005-05-02 | 2015-03-31 | Merck And Co., Inc. | Hcv ns3 protease inhibitors |
CA2607359C (en) | 2005-05-13 | 2011-08-09 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
CN101242842A (zh) | 2005-06-17 | 2008-08-13 | 诺瓦提斯公司 | Sanglifehrin在hcv中的用途 |
TWI387603B (zh) | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Hcv ns3蛋白酶抑制劑 |
US8278322B2 (en) | 2005-08-01 | 2012-10-02 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
AR056191A1 (es) * | 2005-08-23 | 2007-09-26 | Idenix Phatmaceuticals Inc | Anillo de nucleosidos de siete miembros como inhibidores de la replica viral, metodos para su sintesis, composiciones farmaceuticas que los contienen y su uso en el tratamiento de infecciones con virus de la familia flaviviridae |
GB0523041D0 (en) * | 2005-11-11 | 2005-12-21 | Cyclacel Ltd | Combination |
NZ568909A (en) | 2005-12-09 | 2011-10-28 | Hoffmann La Roche | Antiviral 4-fluoro-4-methyl nucleoside prodrugs |
CN102702194A (zh) | 2005-12-21 | 2012-10-03 | 雅培制药有限公司 | 抗病毒化合物 |
WO2007076034A2 (en) | 2005-12-21 | 2007-07-05 | Abbott Laboratories | Anti-viral compounds |
WO2007081517A2 (en) | 2005-12-21 | 2007-07-19 | Abbott Laboratories | Anti-viral compounds |
EP2345652A1 (en) | 2005-12-21 | 2011-07-20 | Abbott Laboratories | Antiviral compounds |
US7781576B2 (en) | 2005-12-23 | 2010-08-24 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
EP1987050A2 (en) * | 2006-02-14 | 2008-11-05 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
US8895531B2 (en) | 2006-03-23 | 2014-11-25 | Rfs Pharma Llc | 2′-fluoronucleoside phosphonates as antiviral agents |
CN101460488A (zh) | 2006-04-04 | 2009-06-17 | 弗·哈夫曼-拉罗切有限公司 | 用于hcv治疗的3’,5’-二-o-酰化核苷 |
JP5167244B2 (ja) | 2006-04-11 | 2013-03-21 | ノバルティス アーゲー | Hcv/hiv阻害剤およびそれらの使用 |
US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
US8058260B2 (en) * | 2006-05-22 | 2011-11-15 | Xenoport, Inc. | 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof |
GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
US7662958B2 (en) | 2006-07-19 | 2010-02-16 | Rolf Wagner | Anti-infective agents |
SI2084174T1 (sl) | 2006-10-10 | 2013-10-30 | Gilead Pharmasset Llc | Priprava nukleozidov ribofuranozil pririmidinov |
JP2010505902A (ja) | 2006-10-10 | 2010-02-25 | メディヴィル・アクチエボラーグ | Hcvヌクレオシド阻害剤 |
CA2667165A1 (en) | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
AU2007309544B2 (en) | 2006-10-24 | 2012-05-31 | Msd Italia S.R.L. | HCV NS3 protease inhibitors |
CN101583372A (zh) | 2006-10-24 | 2009-11-18 | 默克公司 | Hcv ns3蛋白酶抑制剂 |
JP5352464B2 (ja) | 2006-10-27 | 2013-11-27 | メルク・シャープ・アンド・ドーム・コーポレーション | Hcvns3プロテアーゼ阻害剤 |
KR101615500B1 (ko) | 2006-10-27 | 2016-04-27 | 머크 샤프 앤드 돔 코포레이션 | Hcv ns3 프로테아제 억제제 |
KR101165936B1 (ko) | 2006-11-09 | 2012-07-19 | 에프. 호프만-라 로슈 아게 | 티아졸 및 옥사졸-치환된 아릴아마이드 |
BRPI0718915A2 (pt) | 2006-11-15 | 2013-12-03 | Virochem Pharma Inc | Análogos de tiofeno para o tratamento ou prevenção de infecções por flavivírus |
GB0623493D0 (en) | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
GB0625283D0 (en) | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
GB0625349D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
TWI399380B (zh) | 2006-12-20 | 2013-06-21 | Abbott Lab | 抗病毒化合物 |
GB0625345D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
CA2672250C (en) | 2006-12-20 | 2013-04-30 | Ian Stansfield | Antiviral indoles |
CA2672613A1 (en) * | 2006-12-20 | 2008-07-03 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection |
US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
AU2007342367B2 (en) | 2007-01-05 | 2012-12-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
US8361988B2 (en) * | 2007-01-17 | 2013-01-29 | Institut De Recherches Cliniques De Montreal | Nucleoside and nucleotide analogues with quaternary carbon centers and methods of use |
PL2144604T3 (pl) | 2007-02-28 | 2012-02-29 | Conatus Pharmaceuticals Inc | Sposoby leczenia przewlekłego zapalenia wątroby typu C z zastosowaniem RO 113-0830 |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
GB0709791D0 (en) * | 2007-05-22 | 2007-06-27 | Angeletti P Ist Richerche Bio | Antiviral agents |
CN101754970B (zh) | 2007-07-17 | 2013-07-10 | P.安杰莱蒂分子生物学研究所 | 用于治疗丙型肝炎的大环吲哚衍生物 |
CA2699891C (en) | 2007-07-19 | 2013-10-22 | Nigel Liverton | Macrocyclic compounds as antiviral agents |
JP5734655B2 (ja) | 2007-09-17 | 2015-06-17 | アッヴィ・バハマズ・リミテッド | 抗感染症ピリミジンおよびその使用 |
CN101801935B (zh) * | 2007-09-17 | 2014-12-03 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
US8178548B2 (en) | 2007-09-17 | 2012-05-15 | Abbott Laboratories | Anti-infective agents and uses thereof |
SI2234976T1 (sl) | 2007-12-17 | 2013-07-31 | F. Hoffmann-La Roche Ag | Novi s pirazolom substituirani arilamidi |
CA2708228C (en) | 2007-12-17 | 2016-06-21 | F. Hoffmann-La Roche Ag | Tetrazole-substituted arylamide derivatives and their use as p2x3 and/or p2x2/3 purinergic receptor antagonists |
WO2009077365A1 (en) | 2007-12-17 | 2009-06-25 | F. Hoffmann-La Roche Ag | Novel imidazole-substituted arylamides |
KR101405746B1 (ko) | 2007-12-17 | 2014-06-10 | 에프. 호프만-라 로슈 아게 | 트리아졸 치환된 아릴아미드 유도체 및 p2x3 및/또는 p2x2/3 퓨린성 수용체 길항제로서의 용도 |
US8227431B2 (en) | 2008-03-17 | 2012-07-24 | Hetero Drugs Limited | Nucleoside derivatives |
EP2265626B1 (en) * | 2008-03-18 | 2019-05-15 | LCB Pharma Inc | Nucleotide analogues with quaternary carbon stereogenic centers and methods of use |
TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
PT2268642E (pt) | 2008-04-23 | 2015-06-02 | Gilead Sciences Inc | Análogos de carba-nulceósidos 1¿-substituídos para tratamento antiviral |
JP2011518882A (ja) | 2008-04-28 | 2011-06-30 | メルク・シャープ・エンド・ドーム・コーポレイション | Hcvns3プロテアーゼ阻害剤 |
CA2725295C (en) | 2008-06-09 | 2016-11-08 | Cyclacel Limited | Combination of sapacitabine (cndac) and dna methyltransferase inhibitors such as decitabine and procaine |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
CA2729168A1 (en) * | 2008-07-02 | 2010-02-04 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
EP2313102A2 (en) | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
CA2729769C (en) * | 2008-07-08 | 2017-09-05 | Gilead Sciences, Inc. | Salts of hiv inhibitor compounds |
DK2310095T3 (da) | 2008-07-22 | 2012-12-10 | Merck Sharp & Dohme | Makrocykliske quinoxalinforbindelser som hcv-ns3-protease-inhibitorer |
WO2010039801A2 (en) | 2008-10-02 | 2010-04-08 | The J. David Gladstone Institutes | Methods of treating hepatitis c virus infection |
EA019295B1 (ru) * | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Соединения пуриновых нуклеозидов и способ их получения |
EP2376088B1 (en) | 2008-12-23 | 2017-02-22 | Gilead Pharmasset LLC | 6-O-Substituted-2-amino-purine nucleoside phosphoramidates |
US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
BRPI1004575A2 (pt) * | 2009-01-09 | 2016-04-05 | Inhibitex Inc | composto, composição farmacêutica, método de tratamento de infecções virais, método de separação dos diaestereômeros de fósforo |
WO2010082050A1 (en) | 2009-01-16 | 2010-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections |
GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
CA2751458C (en) | 2009-02-06 | 2018-06-05 | Rfs Pharma, Llc | Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections |
ES2628842T3 (es) | 2009-02-10 | 2017-08-04 | Gilead Sciences, Inc. | Método para la preparación de tieno[3,4-d]pirimidin-7-il ribósidos |
JP5690286B2 (ja) | 2009-03-04 | 2015-03-25 | イデニク プハルマセウティカルス,インコーポレイテッド | ホスホチオフェン及びホスホチアゾールhcvポリメラーゼ阻害剤 |
EP2408449A4 (en) | 2009-03-18 | 2012-08-08 | Univ Leland Stanford Junior | METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS |
BRPI1009324A2 (pt) * | 2009-03-20 | 2015-11-24 | Alios Biopharma Inc | compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
WO2010132163A1 (en) | 2009-05-13 | 2010-11-18 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis c virus inhibitors |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
US8476457B2 (en) | 2009-06-22 | 2013-07-02 | Roche Palo Alto Llc | Indole, indazole and benzimidazole arylamides as P2X3 and P2X2/3 antagonists |
JP5465782B2 (ja) | 2009-06-22 | 2014-04-09 | エフ.ホフマン−ラ ロシュ アーゲー | 新規オキサゾロン及びピロリジノン置換アリールアミド |
CA2764956A1 (en) | 2009-06-22 | 2010-12-29 | F. Hoffmann-La Roche Ag | Novel biphenyl and phenyl-pyridine amides |
EP2459582B1 (en) | 2009-07-30 | 2015-05-27 | Merck Sharp & Dohme Corp. | Hepatitis c virus ns3 protease inhibitors |
TW201117812A (en) | 2009-08-05 | 2011-06-01 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
KR101818779B1 (ko) | 2009-09-21 | 2018-01-15 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 치료용 2'―플루오로 치환된 카바-뉴클레오사이드 유사체 |
US8455451B2 (en) | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
WO2011035250A1 (en) | 2009-09-21 | 2011-03-24 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs |
US7973013B2 (en) | 2009-09-21 | 2011-07-05 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
BR112012011221A2 (pt) | 2009-11-14 | 2016-04-05 | Hoffmann La Roche | biomarcadores para prever resposta rápida ao tratamento de hcv |
US20110117055A1 (en) | 2009-11-19 | 2011-05-19 | Macdonald James E | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds |
MX2012006026A (es) | 2009-11-25 | 2012-08-15 | Vertex Pharma | Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus. |
RU2012127201A (ru) | 2009-12-02 | 2014-01-20 | Ф.Хоффманн-Ля Рош Аг | Биомаркеры для прогнозирования устойчивого ответа на лечение вируса гепатита с |
RU2554087C2 (ru) | 2009-12-18 | 2015-06-27 | Айденикс Фармасьютикалз, Инк. | 5,5-конденсированные ариленовые или гетероариленовые ингибиторы вируса гепатита с |
JP2013515746A (ja) | 2009-12-24 | 2013-05-09 | ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド | フラビウイルス感染症の治療又は予防のための類似体 |
US9216952B2 (en) | 2010-03-23 | 2015-12-22 | Abbvie Inc. | Process for preparing antiviral compound |
US20130102652A1 (en) * | 2010-03-23 | 2013-04-25 | University Of Utah Research Foundation | Methods and compositions related to modified adenosines for controlling off-target effects in rna interference |
EP2550278A1 (en) | 2010-03-24 | 2013-01-30 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
MX2012010918A (es) | 2010-03-24 | 2013-01-18 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones por flavivirus. |
TW201141857A (en) | 2010-03-24 | 2011-12-01 | Vertex Pharma | Analogues for the treatment or prevention of flavivirus infections |
WO2011119858A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
JP2013527145A (ja) | 2010-03-31 | 2013-06-27 | ギリード・ファーマセット・エルエルシー | リン含有活性化剤の立体選択的合成 |
US8680071B2 (en) | 2010-04-01 | 2014-03-25 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
EP2582717A2 (en) | 2010-06-15 | 2013-04-24 | Vertex Pharmaceuticals Incorporated | Hcv ns5b polymerase mutants |
JP2013531011A (ja) | 2010-06-28 | 2013-08-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染の処置または予防のための化合物および方法 |
WO2012006055A2 (en) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
WO2012006070A1 (en) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
EP2593439B1 (en) | 2010-07-16 | 2016-08-17 | AbbVie Bahamas Ltd. | Process for preparing antiviral compounds |
EP3461556A1 (en) | 2010-07-16 | 2019-04-03 | AbbVie Ireland Unlimited Company | Phosphine ligands for catalytic reactions |
US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
KR101995598B1 (ko) | 2010-07-19 | 2019-07-02 | 길리애드 사이언시즈, 인코포레이티드 | 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법 |
PL2595980T3 (pl) | 2010-07-22 | 2015-03-31 | Gilead Sciences Inc | Sposoby i związki do leczenia infekcji wirusowych Paramyxoviridae |
JP2013534249A (ja) | 2010-08-17 | 2013-09-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス科ウイルス感染の処置または予防のための化合物および方法 |
PE20171624A1 (es) | 2010-09-20 | 2017-11-02 | Gilead Sciences Inc | Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral |
EA029145B1 (ru) | 2010-09-21 | 2018-02-28 | Энанта Фармасьютикалз, Инк. | Ингибиторы hcv сериновой протеазы, полученные из макроциклического пролина |
BR112013005872A2 (pt) | 2010-09-22 | 2019-09-24 | Alios Biopharma Inc | compostos, composição farmacêutica e respectivos usos |
EP2624826B1 (en) | 2010-10-08 | 2018-07-18 | Novartis AG | Vitamin e formulations of sulfamide ns3 inhibitors |
AR084044A1 (es) | 2010-11-30 | 2013-04-17 | Pharmasset Inc | Compuestos 2’-espiro-nucleosidos |
WO2012080050A1 (en) | 2010-12-14 | 2012-06-21 | F. Hoffmann-La Roche Ag | Solid forms of a phenoxybenzenesulfonyl compound |
EP2658857B1 (en) * | 2010-12-29 | 2016-11-02 | Inhibitex, Inc. | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections |
AR085352A1 (es) | 2011-02-10 | 2013-09-25 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv |
JP2014514295A (ja) | 2011-03-31 | 2014-06-19 | アイディニックス ファーマシューティカルズ インコーポレイテッド | ウイルス感染の治療のための化合物および薬学的組成物 |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
WO2012142523A2 (en) * | 2011-04-13 | 2012-10-18 | Gilead Sciences, Inc. | 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment |
WO2012142093A2 (en) * | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
BR112013026345A2 (pt) | 2011-04-13 | 2019-04-24 | Merck Sharp & Dohe Corp. | composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv |
EP2697242B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
EP2696878B1 (en) | 2011-04-14 | 2019-07-10 | Cyclacel Limited | Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia |
CN102775458B (zh) * | 2011-05-09 | 2015-11-25 | 中国人民解放军军事医学科学院毒物药物研究所 | β-D-(2’R)-2’-脱氧—2’-氟-2’-C-甲基胞苷衍生物的制备及用途 |
CN103687866A (zh) * | 2011-05-19 | 2014-03-26 | Rfs制药公司 | 用于治疗病毒性感染的嘌呤单磷酸酯前药 |
US9416154B2 (en) | 2011-07-13 | 2016-08-16 | Merck Sharp & Dohme Corp. | 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
WO2013009737A1 (en) | 2011-07-13 | 2013-01-17 | Merck Sharp & Dohme Corp. | 5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases |
WO2013016499A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Methods for preparation of thiophene compounds |
TW201313697A (zh) | 2011-07-26 | 2013-04-01 | Vertex Pharma | 製備噻吩化合物之方法 |
JP2014526474A (ja) | 2011-09-12 | 2014-10-06 | アイディニックス ファーマシューティカルズ インコーポレイテッド | ウイルス感染の治療のための化合物および薬学的組成物 |
EP2755983B1 (en) | 2011-09-12 | 2017-03-15 | Idenix Pharmaceuticals LLC. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
JP6073897B2 (ja) | 2011-09-16 | 2017-02-01 | ギリアド ファーマセット エルエルシー | Hcvを処置するための方法 |
EP2768838A1 (en) | 2011-10-14 | 2014-08-27 | IDENIX Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
EP2780026B1 (en) | 2011-11-15 | 2019-10-23 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
AU2012345732B2 (en) | 2011-11-30 | 2016-07-14 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
CN104066432B (zh) | 2011-12-06 | 2017-06-13 | 小利兰·斯坦福大学董事会 | 用于治疗病毒性疾病的方法和组合物 |
AU2012358804B2 (en) | 2011-12-22 | 2018-04-19 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
US20140356325A1 (en) | 2012-01-12 | 2014-12-04 | Ligand Pharmaceuticals Incorporated | Novel 2'-c-methyl nucleoside derivative compounds |
WO2013133927A1 (en) | 2012-02-13 | 2013-09-12 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate] |
AU2013221571A1 (en) | 2012-02-14 | 2014-08-28 | University Of Georgia Research Foundation, Inc. | Spiro [2.4] heptanes for treatment of Flaviviridae infections |
US8916538B2 (en) | 2012-03-21 | 2014-12-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
EP2827876A4 (en) | 2012-03-22 | 2015-10-28 | Alios Biopharma Inc | PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG |
SG11201407674TA (en) | 2012-05-22 | 2014-12-30 | Idenix Pharmaceuticals Inc | D-amino acid compounds for liver disease |
WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
EP2852605B1 (en) | 2012-05-22 | 2018-01-31 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphate prodrugs for hcv infection |
PL2861611T3 (pl) | 2012-05-25 | 2017-08-31 | Janssen Sciences Ireland Uc | Nukleozydy uracylowe spirooksetanu |
US9556216B2 (en) | 2012-08-31 | 2017-01-31 | Novartis Ag | 2′-Ethynyl nucleoside derivatives for treatment of viral infections |
WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
WO2014049540A2 (en) | 2012-09-29 | 2014-04-03 | Novartis Ag | Cyclic peptides and use as medicines |
TR201809048T4 (tr) | 2012-10-08 | 2018-07-23 | Centre Nat Rech Scient | Hcv enfeksiyonu için 2'-kloro nükleosit analogları. |
US20140112886A1 (en) | 2012-10-19 | 2014-04-24 | Idenix Pharmaceuticals, Inc. | Dinucleotide compounds for hcv infection |
US10723754B2 (en) | 2012-10-22 | 2020-07-28 | Idenix Pharmaceuticals Llc | 2′,4′-bridged nucleosides for HCV infection |
WO2014078436A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of sp-nucleoside analog |
EP2920195A1 (en) | 2012-11-14 | 2015-09-23 | IDENIX Pharmaceuticals, Inc. | D-alanine ester of rp-nucleoside analog |
WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
EA201590943A1 (ru) | 2012-12-21 | 2016-01-29 | Алиос Биофарма, Инк. | Замещенные нуклеозиды, нуклеотиды и их аналоги |
ES2771458T3 (es) | 2013-01-31 | 2020-07-06 | Gilead Pharmasset Llc | Formulación de combinación de dos compuestos antivirales |
US10034893B2 (en) | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
WO2014121417A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
WO2014121418A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
WO2014134251A1 (en) | 2013-02-28 | 2014-09-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
EP2970358B1 (en) | 2013-03-04 | 2021-06-30 | Idenix Pharmaceuticals LLC | 3'-deoxy nucleosides for the treatment of hcv |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
EP2970357A1 (en) | 2013-03-13 | 2016-01-20 | IDENIX Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
RU2534613C2 (ru) | 2013-03-22 | 2014-11-27 | Александр Васильевич Иващенко | Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения |
US9187515B2 (en) | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
RU2015148006A (ru) | 2013-04-12 | 2017-05-18 | Ачиллион Фармасютикалз, Инк. | Дейтерированные нуклеозидные пролекарства, применимые для лечения hcv |
WO2014197578A1 (en) | 2013-06-05 | 2014-12-11 | Idenix Pharmaceuticals, Inc. | 1',4'-thio nucleosides for the treatment of hcv |
US20150037282A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
US9326983B2 (en) | 2013-08-01 | 2016-05-03 | University Of Kentucky Research Foundation | Compositions and methods for treating retinal degradation |
PL3650014T3 (pl) | 2013-08-27 | 2022-01-31 | Gilead Pharmasset Llc | Preparat złożony dwóch związków przeciwwirusowych |
EP3043803B1 (en) * | 2013-09-11 | 2022-04-27 | Emory University | Nucleotide and nucleoside compositions and their uses |
EP3046924A1 (en) | 2013-09-20 | 2016-07-27 | IDENIX Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
WO2015061683A1 (en) | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv |
US20160271162A1 (en) | 2013-11-01 | 2016-09-22 | Idenix Pharmacueticals, Llc | D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv |
CN104211748B (zh) * | 2013-11-15 | 2017-05-31 | 南京济群医药科技股份有限公司 | 6‑羟基双脱氧鸟嘌呤核苷磷酸酯制备和用途 |
US20170198005A1 (en) | 2013-11-27 | 2017-07-13 | Idenix Pharmaceuticals Llc | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
WO2015095419A1 (en) | 2013-12-18 | 2015-06-25 | Idenix Pharmaceuticals, Inc. | 4'-or nucleosides for the treatment of hcv |
EP3105238A4 (en) | 2014-02-13 | 2017-11-08 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
WO2015134780A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv |
US20170135990A1 (en) | 2014-03-05 | 2017-05-18 | Idenix Pharmaceuticals Llc | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
WO2015134560A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
EP3131914B1 (en) * | 2014-04-16 | 2023-05-10 | Idenix Pharmaceuticals LLC | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
EP3164136A4 (en) | 2014-07-02 | 2018-04-04 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and uses therof |
US9675632B2 (en) | 2014-08-26 | 2017-06-13 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
TWI687432B (zh) | 2014-10-29 | 2020-03-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
US9718851B2 (en) | 2014-11-06 | 2017-08-01 | Enanta Pharmaceuticals, Inc. | Deuterated nucleoside/tide derivatives |
US9732110B2 (en) | 2014-12-05 | 2017-08-15 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
CN107428792B (zh) * | 2014-12-15 | 2023-01-24 | 埃默里大学 | 用于治疗乙型肝炎病毒的磷酰胺 |
EP3858826A1 (en) * | 2015-02-26 | 2021-08-04 | University of Kentucky Research Foundation | Compositions and methods for treating retinal degradation |
US11219623B2 (en) | 2015-02-26 | 2022-01-11 | University Of Kentucky Research Foundation | Inflammasome inhibition for the treatment of Parkinson's disease, Alzheimer's disease and multiple sclerosis |
IL295418B2 (en) | 2015-03-06 | 2023-10-01 | Atea Pharmaceuticals Inc | Cell-D-2'-deoxy-2'-alpha-fluoro-2'-cell-C-modified-2-different-N6-purine modified nucleotides for the treatment of hepatitis C virus |
WO2017040766A1 (en) | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral tetrahydrofurane derivatives |
ES2918585T3 (es) | 2015-09-16 | 2022-07-19 | Gilead Sciences Inc | Métodos para el tratamiento de infecciones por el virus Arenaviridae |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
EP3454856A4 (en) | 2016-05-10 | 2019-12-25 | C4 Therapeutics, Inc. | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
EA201990059A1 (ru) | 2016-06-24 | 2019-07-31 | Эмори Юниверсити | Фосфорамидаты для лечения вируса гепатита b |
US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
LU100724B1 (en) | 2016-07-14 | 2018-07-31 | Atea Pharmaceuticals Inc | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
PT3512863T (pt) | 2016-09-07 | 2022-03-09 | Atea Pharmaceuticals Inc | Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna |
KR102335193B1 (ko) | 2017-02-01 | 2021-12-03 | 아테아 파마슈티컬즈, 인크. | C형 간염 바이러스를 치료하기 위한 뉴클레오티드 헤미-술페이트 염 |
EP3595672B1 (en) | 2017-03-14 | 2023-09-06 | Gilead Sciences, Inc. | Compounds for use in methods of treating feline coronavirus infections |
ES2938859T3 (es) | 2017-05-01 | 2023-04-17 | Gilead Sciences Inc | Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato |
EP3645836A4 (en) | 2017-06-26 | 2021-04-07 | HRL Laboratories, LLC | SYSTEM AND PROCESS FOR THE PRODUCTION OF INERTIAL BOTTOM-OF-HOLE MEASUREMENT UNIT OUTPUT |
EP3651734A1 (en) | 2017-07-11 | 2020-05-20 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
EP3960740B1 (en) | 2017-08-01 | 2023-11-15 | Gilead Sciences, Inc. | Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) vanillate for treating viral infections |
CN111788196A (zh) | 2018-01-09 | 2020-10-16 | 配体药物公司 | 缩醛化合物及其治疗用途 |
CN112351799A (zh) | 2018-04-10 | 2021-02-09 | 阿堤亚制药公司 | 具有硬化的hcv感染患者的治疗 |
JP2022512751A (ja) * | 2018-10-17 | 2022-02-07 | リャオ,シビン | 6-メルカプトプリンヌクレオシドアナログ |
EP3891508A1 (en) | 2018-12-04 | 2021-10-13 | Bristol-Myers Squibb Company | Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring |
JP2023512656A (ja) | 2020-01-27 | 2023-03-28 | ギリアード サイエンシーズ, インコーポレイテッド | SARS CoV-2感染を治療するための方法 |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
TWI785528B (zh) | 2020-03-12 | 2022-12-01 | 美商基利科學股份有限公司 | 1’-氰基核苷之製備方法 |
KR20220164784A (ko) | 2020-04-06 | 2022-12-13 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형 |
EP4157272A1 (en) | 2020-05-29 | 2023-04-05 | Gilead Sciences, Inc. | Remdesivir treatment methods |
TWI819321B (zh) | 2020-06-24 | 2023-10-21 | 美商基利科學股份有限公司 | 1'-氰基核苷類似物及其用途 |
WO2022008025A1 (en) * | 2020-07-05 | 2022-01-13 | Since & Technology Development Fund Authority | 2-hydroxyiminopyrimidine nucleosides and derivitives and antiviral uses thereto |
IL300412A (en) | 2020-08-24 | 2023-04-01 | Gilead Sciences Inc | Phospholipid compounds and their uses |
TW202228722A (zh) | 2020-08-27 | 2022-08-01 | 美商基利科學股份有限公司 | 用於治療病毒感染之化合物及方法 |
TWI811812B (zh) | 2020-10-16 | 2023-08-11 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
EP4320128A1 (en) | 2022-03-02 | 2024-02-14 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
Family Cites Families (383)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE140254C (US20040097461A1-20040520-C00002.png) | ||||
US50229A (en) * | 1865-10-03 | Improvement in cultivators | ||
US83307A (en) * | 1868-10-20 | Improvement in wash-boilehs | ||
US28013A (en) * | 1860-04-24 | Improved bullet-ladle | ||
US19363A (en) * | 1858-02-16 | Improved harpoon-and lance | ||
US55483A (en) * | 1866-06-12 | Improvement in pruning-hooks | ||
US8841A (en) * | 1852-03-30 | Sice-httxieb | ||
US87873A (en) * | 1869-03-16 | Perry prettyman | ||
US147160A (en) * | 1874-02-03 | Improvement in seed-planters | ||
US6458772B1 (en) | 1909-10-07 | 2002-10-01 | Medivir Ab | Prodrugs |
US3074929A (en) | 1955-08-11 | 1963-01-22 | Burroughs Wellcome Co | Glycosides of 6-mercaptopurine |
GB924246A (en) | 1958-12-23 | 1963-04-24 | Wellcome Found | Purine derivatives and their preparation |
US3116282A (en) | 1960-04-27 | 1963-12-31 | Upjohn Co | Pyrimidine nucleosides and process |
GB984877A (en) | 1962-08-16 | 1965-03-03 | Waldhof Zellstoff Fab | Improvements in and relating to 6-halonucleosides |
FR1498856A (US20040097461A1-20040520-C00002.png) | 1965-11-15 | 1968-01-10 | ||
GB1163103A (en) * | 1965-11-15 | 1969-09-04 | Merck & Co Inc | Ribofuranosyl Purine Derivatives |
DE1695411A1 (de) | 1966-05-02 | 1971-04-15 | Merck & Co Inc | Substituierte Purin-Nucleoside und Verfahren zu deren Herstellung |
FR1521076A (fr) * | 1966-05-02 | 1968-04-12 | Merck & Co Inc | Nucléosides de purines substituées |
US3480613A (en) | 1967-07-03 | 1969-11-25 | Merck & Co Inc | 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof |
JPS4621872Y1 (US20040097461A1-20040520-C00002.png) | 1968-02-27 | 1971-07-28 | ||
DE2122991C2 (de) * | 1971-05-04 | 1982-06-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden |
US3798209A (en) | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
USRE29835E (en) | 1971-06-01 | 1978-11-14 | Icn Pharmaceuticals | 1,2,4-Triazole nucleosides |
JPS4848495A (US20040097461A1-20040520-C00002.png) | 1971-09-21 | 1973-07-09 | ||
US4022889A (en) | 1974-05-20 | 1977-05-10 | The Upjohn Company | Therapeutic compositions of antibiotic U-44,590 and methods for using the same |
DE2508312A1 (de) | 1975-02-24 | 1976-09-02 | Schering Ag | Neues verfahren zur herstellung von nucleosiden |
US4058602A (en) | 1976-08-09 | 1977-11-15 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Synthesis, structure, and antitumor activity of 5,6-dihydro-5-azacytidine |
DE2757365A1 (de) | 1977-12-20 | 1979-06-21 | Schering Ag | Neues verfahren zur herstellung von nucleosiden |
DE2852721A1 (de) | 1978-12-06 | 1980-06-26 | Basf Ag | Verfahren zur reindarstellung von kaliumribonat und ribonolacton |
US4239753A (en) | 1978-12-12 | 1980-12-16 | The Upjohn Company | Composition of matter and process |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
FR2562543B1 (fr) | 1984-04-10 | 1987-09-25 | Elf Aquitaine | Nouveaux phosphonites cycliques, leur preparation et applications |
NL8403224A (nl) | 1984-10-24 | 1986-05-16 | Oce Andeno Bv | Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen. |
KR880000094B1 (ko) | 1984-12-07 | 1988-02-23 | 보령제약 주식회사 | 뉴클레오시드 유도체의 제조방법 |
JPS61204193A (ja) | 1985-03-05 | 1986-09-10 | Takeda Chem Ind Ltd | シトシンヌクレオシド類の製造法 |
US6448392B1 (en) | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
JPS61212592A (ja) | 1985-03-19 | 1986-09-20 | Tokyo Tanabe Co Ltd | D−リボ−スの製造方法 |
US4605659A (en) | 1985-04-30 | 1986-08-12 | Syntex (U.S.A.) Inc. | Purinyl or pyrimidinyl substituted hydroxycyclopentane compounds useful as antivirals |
JPS61263995A (ja) | 1985-05-16 | 1986-11-21 | Takeda Chem Ind Ltd | シトシンヌクレオシド類の製造法 |
US4754026A (en) | 1985-06-04 | 1988-06-28 | Takeda Chemical Industries, Ltd. | Conversion of uracil derivatives to cytosine derivatives |
US5455339A (en) | 1986-05-01 | 1995-10-03 | University Of Georgia Research Foundation, Inc. | Method for the preparation of 2',3'-dideoxy and 2',3'-dideoxydide-hydro nucleosides |
JPH0699467B2 (ja) | 1987-03-04 | 1994-12-07 | ヤマサ醤油株式会社 | 2▲’▼−デオキシ−2▲’▼(s)−アルキルピリミジンヌクレオシド誘導体 |
DE3714473A1 (de) | 1987-04-30 | 1988-11-10 | Basf Ag | Kontinuierliches verfahren zur epimerisierung von zuckern, insbesondere von d-arabinose zu d-ribose |
GB8719367D0 (en) | 1987-08-15 | 1987-09-23 | Wellcome Found | Therapeutic compounds |
US5246924A (en) | 1987-09-03 | 1993-09-21 | Sloan-Kettering Institute For Cancer Research | Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil |
JPH03501253A (ja) | 1987-09-22 | 1991-03-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | エイズ(aids)治療を目的とするリポソームによるヌクレオシド類似物質 |
US4880784A (en) | 1987-12-21 | 1989-11-14 | Brigham Young University | Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives |
NZ229453A (en) | 1988-06-10 | 1991-08-27 | Univ Minnesota & Southern Rese | A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents |
US5122517A (en) | 1988-06-10 | 1992-06-16 | Regents Of The University Of Minnesota | Antiviral combination comprising nucleoside analogs |
GB8815265D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
US6252060B1 (en) * | 1988-07-07 | 2001-06-26 | Nexstar Pharmaceuticals, Inc. | Antiviral liponucleosides: treatment of hepatitis B |
US6599887B2 (en) * | 1988-07-07 | 2003-07-29 | Chimerix, Inc. | Methods of treating viral infections using antiviral liponucleotides |
SE8802687D0 (sv) | 1988-07-20 | 1988-07-20 | Astra Ab | Nucleoside derivatives |
US5744600A (en) | 1988-11-14 | 1998-04-28 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Phosphonomethoxy carbocyclic nucleosides and nucleotides |
US5616702A (en) | 1988-11-15 | 1997-04-01 | Merrell Pharmaceuticals Inc. | 2-'-ethenylidene cytidine, uridine and guanosine derivatives |
US5705363A (en) | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
US5118672A (en) | 1989-07-10 | 1992-06-02 | University Of Georgia Research Foundation | 5'-diphosphohexose nucleoside pharmaceutical compositions |
US5463092A (en) | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
US5026687A (en) | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
US6060592A (en) * | 1990-01-11 | 2000-05-09 | Isis Pharmaceuticals, Inc. | Pyrimidine nucleoside compounds and oligonucleoside compounds containing same |
US5200514A (en) | 1990-01-19 | 1993-04-06 | University Of Georgia Research Foundation, Inc. | Synthesis of 2'-deoxypyrimidine nucleosides |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US5969109A (en) | 1990-02-28 | 1999-10-19 | Bona; Constantin | Chimeric antibodies comprising antigen binding sites and B and T cell epitopes |
DE69133402T2 (de) | 1990-04-04 | 2004-11-11 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Protease von hepatitis-c-virus |
US5443965A (en) | 1990-04-06 | 1995-08-22 | Genelabs Incorporated | Hepatitis C virus epitopes |
AU7872491A (en) | 1990-05-07 | 1991-11-27 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
FR2662165B1 (fr) * | 1990-05-18 | 1992-09-11 | Univ Paris Curie | Derives nucleosidiques branches, leur procede de preparation et leur utilisation a titre de medicament. |
EP0531452A4 (en) | 1990-05-29 | 1993-06-09 | Vical, Inc. | Synthesis of glycerol di- and triphosphate derivatives |
CA2083961A1 (en) | 1990-05-29 | 1991-11-30 | Henk Van Den Bosch | Synthesis of glycerol di- and triphosphate derivatives |
ES2083580T3 (es) | 1990-06-13 | 1996-04-16 | Arnold Glazier | Profarmacos de fosforo. |
US5627165A (en) | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5827819A (en) | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
US5256641A (en) | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
US5149794A (en) | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
US5543389A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
IL100502A (en) | 1991-01-03 | 1995-12-08 | Iaf Biochem Int | PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (- |
JPH04266880A (ja) | 1991-02-22 | 1992-09-22 | Japan Tobacco Inc | 3 −dpa− ラクトンの製造方法 |
IL101144A (en) | 1991-03-06 | 1996-09-12 | Wellcome Found | Pharmaceutical preparations containing 1 -) 2 -) hydroxymethyl (- 1, 3 - oxathiolan-5 - il (5) fluorescitosin and its derivatives for the treatment of their hepatitis B virus infections |
WO1992018517A1 (en) | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
US5157027A (en) | 1991-05-13 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Bisphosphonate squalene synthetase inhibitors and method |
JPH07500573A (ja) | 1991-07-12 | 1995-01-19 | ネクススター・ファーマシューティカルズ・インコーポレイテッド | 抗ウィルス性リポヌクレオシド:b型肝炎の治療 |
JPH0525152A (ja) | 1991-07-22 | 1993-02-02 | Japan Tobacco Inc | 3−dpa−ラクトンの製造法 |
US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
TW224053B (US20040097461A1-20040520-C00002.png) | 1991-09-13 | 1994-05-21 | Paul B Chretien | |
US5676942A (en) | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
ZA931934B (en) | 1992-03-18 | 1993-03-18 | Us Bioscience | Compostitions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals |
US5610054A (en) | 1992-05-14 | 1997-03-11 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecule targeted against Hepatitis C virus |
US5256797A (en) | 1992-06-22 | 1993-10-26 | Eli Lilly And Company | Process for separating 2-deoxy-2,2-difluoro-D-ribofuranosyl alkylsulfonate anomers |
US5606048A (en) * | 1992-06-22 | 1997-02-25 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5401861A (en) | 1992-06-22 | 1995-03-28 | Eli Lilly And Company | Low temperature process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates |
US5371210A (en) | 1992-06-22 | 1994-12-06 | Eli Lilly And Company | Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5821357A (en) | 1992-06-22 | 1998-10-13 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides |
WO1994001117A1 (en) * | 1992-07-02 | 1994-01-20 | The Wellcome Foundation Limited | Therapeutic nucleosides |
DE4224737A1 (de) | 1992-07-27 | 1994-02-03 | Herbert Prof Dr Schott | Neue Cytosinnucleosidanaloga, Verfahren zu ihrer Herstellung und ihre Verwendung |
HU214980B (hu) | 1992-09-01 | 1998-08-28 | Eli Lilly And Co. | Eljárás nukleozidok anomerizálására |
DE69330372T2 (de) | 1992-09-10 | 2002-03-14 | Isis Pharmaceuticals Inc | ZUSAMMENSETZUNGEN UND VERFAHREN FüR DIE BEHANDLUNG VON MIT HEPATITIS C VIREN ASSOZIIERTEN KRANKHEITEN |
US6423489B1 (en) | 1992-09-10 | 2002-07-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
US6174868B1 (en) | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
US6433159B1 (en) | 1992-09-10 | 2002-08-13 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus associated diseases |
US6391542B1 (en) | 1992-09-10 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
US6057093A (en) | 1992-09-28 | 2000-05-02 | Chiron Corporation | Methods and compositions for controlling translation of HCV proteins |
JPH06135988A (ja) | 1992-10-22 | 1994-05-17 | Toagosei Chem Ind Co Ltd | ヌクレオシド誘導体 |
GB9226729D0 (en) | 1992-12-22 | 1993-02-17 | Wellcome Found | Therapeutic combination |
JPH06211890A (ja) | 1993-01-12 | 1994-08-02 | Yamasa Shoyu Co Ltd | 2’−デオキシ−2’(s)−置換アルキルシチジン誘導体 |
JPH06228186A (ja) | 1993-01-29 | 1994-08-16 | Yamasa Shoyu Co Ltd | 2’−デオキシ−(2’s)−アルキルピリミジンヌクレオシド誘導体 |
EP0686043B1 (en) | 1993-02-24 | 1999-06-23 | WANG, Jui, H. | Compositions and methods of application of reactive antiviral polymers |
US5738985A (en) | 1993-04-02 | 1998-04-14 | Ribogene, Inc. | Method for selective inactivation of viral replication |
GB9307043D0 (en) | 1993-04-05 | 1993-05-26 | Norsk Hydro As | Chemical compounds |
JP3693357B2 (ja) | 1993-04-09 | 2005-09-07 | 峯郎 実吉 | 逆転写酵素阻害剤 |
WO1994026273A1 (en) | 1993-05-12 | 1994-11-24 | Hostetler Karl Y | Acyclovir derivatives for topical use |
WO1994028908A2 (en) | 1993-06-10 | 1994-12-22 | Wake Forest University | (phospho)lipids for combatting hepatitis b virus infection |
CA2167537A1 (en) | 1993-07-19 | 1995-02-02 | Tsuneo Ozeki | Hepatitis c virus proliferation inhibitor |
US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
US5587362A (en) | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
IT1272179B (it) | 1994-02-23 | 1997-06-16 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv. |
DE4447588C2 (de) | 1994-05-03 | 1997-11-20 | Omer Osama Dr Dr Med | Pflanzliches Arzneimittel zur Behandlung von chronischen und allergischen Rhino-Sino-Bronchitiden |
JPH10503364A (ja) | 1994-05-10 | 1998-03-31 | ザ ジェネラル ホスピタル コーポレーション | C型肝炎ウイルスのアンチセンス阻害 |
DE4432623A1 (de) | 1994-09-14 | 1996-03-21 | Huels Chemische Werke Ag | Verfahren zur Bleichung von wäßrigen Tensidlösungen |
US5696277A (en) | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
US5763418A (en) | 1994-12-13 | 1998-06-09 | Akira Matsuda | 3'-substituted nucleoside derivatives |
GB9505025D0 (en) | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
JP3786447B2 (ja) | 1995-03-31 | 2006-06-14 | エーザイ株式会社 | C型肝炎の予防・治療剤 |
DE19513330A1 (de) | 1995-04-03 | 1996-10-10 | Schering Ag | Neues Verfahren zur Herstellung von Nucleosiden |
US5977061A (en) * | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
US5861267A (en) | 1995-05-01 | 1999-01-19 | Vertex Pharmaceuticals Incorporated | Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity |
DE19531226C1 (de) | 1995-08-24 | 1997-04-03 | Immuno Ag | Pharmazeutische Zusammensetzungen, enthaltend ein neutralisiertes Virus, und Verwendung derselben |
JPH0959292A (ja) | 1995-08-25 | 1997-03-04 | Yamasa Shoyu Co Ltd | 4−アミノピリミジンヌクレオシドの製造法 |
WO1997009052A1 (en) | 1995-09-07 | 1997-03-13 | University Of Georgia Research Foundation, Inc. | Therapeutic azide compounds |
DE69635864T2 (de) | 1995-09-27 | 2006-10-26 | Emory University | Rekombinante rna-replikase von hepatitis-c-virus |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
US5980884A (en) | 1996-02-05 | 1999-11-09 | Amgen, Inc. | Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon |
AU2064297A (en) | 1996-02-29 | 1997-09-16 | Immusol, Inc | Hepatitis c virus ribozymes |
US5759795A (en) | 1996-03-08 | 1998-06-02 | Schering Corporation | Assay for determining inhibitors of ATPase |
US5633388A (en) | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US5830905A (en) | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US5990276A (en) | 1996-05-10 | 1999-11-23 | Schering Corporation | Synthetic inhibitors of hepatitis C virus NS3 protease |
GB9609932D0 (en) | 1996-05-13 | 1996-07-17 | Hoffmann La Roche | Use of IL-12 and IFN alpha for the treatment of infectious diseases |
US5891874A (en) | 1996-06-05 | 1999-04-06 | Eli Lilly And Company | Anti-viral compound |
US5837257A (en) | 1996-07-09 | 1998-11-17 | Sage R&D | Use of plant extracts for treatment of HIV, HCV and HBV infections |
US5858389A (en) | 1996-08-28 | 1999-01-12 | Shaker H. Elsherbini | Squalene is an antiviral compound for treating hepatitis C virus carriers |
JP3927630B2 (ja) | 1996-09-27 | 2007-06-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウイルス感染症の予防・治療剤 |
US5922757A (en) | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
ATE238328T1 (de) | 1996-10-16 | 2003-05-15 | Ribapharm Inc | Monozyklische l-nukleoside, analoga und ihre anwendungen |
KR100412480B1 (ko) * | 1996-10-16 | 2003-12-31 | 아이씨엔 파마슈티컬스, 인코포레이티드 | 푸린 l-누클레오시드, 이의 유사체 및 이들의 용도 |
UA66767C2 (uk) | 1996-10-18 | 2004-06-15 | Вертекс Фармасьютикалс Інкорпорейтед | Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с |
NZ335000A (en) | 1996-10-28 | 2000-12-22 | Univ Washington | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
IL119833A (en) | 1996-12-15 | 2001-01-11 | Lavie David | Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis |
US6248878B1 (en) * | 1996-12-24 | 2001-06-19 | Ribozyme Pharmaceuticals, Inc. | Nucleoside analogs |
IL130497A0 (en) | 1997-01-17 | 2000-06-01 | Icn Pharmaceuticals | Controlled release preparations to selectively modulate Th1 and Th2 responses |
EP0975809A4 (en) | 1997-03-05 | 2002-10-30 | Univ Washington | EXAMINATION PROCEDURE FOR DETECTING AGENTS FOR SELECTIVE INHIBITION OF HCV REPLICATION |
ATE267198T1 (de) | 1997-03-19 | 2004-06-15 | Univ Emory | Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosiden |
US5849800A (en) | 1997-03-28 | 1998-12-15 | The Penn State Research Foundation | Use of amantadine for treatment of Hepatitis C |
US6004933A (en) | 1997-04-25 | 1999-12-21 | Cortech Inc. | Cysteine protease inhibitors |
DK1009732T3 (da) | 1997-06-30 | 2003-09-22 | Merz Pharma Gmbh & Co Kgaa | 1-Amino-alkylcyclohexan NMDA receptor antagonister |
US6010848A (en) | 1997-07-02 | 2000-01-04 | Smithkline Beecham Corporation | Screening methods using an atpase protein from hepatitis C virus |
JP4452401B2 (ja) | 1997-08-11 | 2010-04-21 | ベーリンガー インゲルハイム (カナダ) リミテッド | C型肝炎ウイルス阻害ペプチドアナログ |
US6472373B1 (en) | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
ES2162393T3 (es) | 1997-09-21 | 2001-12-16 | Schering Corp | Terapia de combinacion para erradicar el hcv-rna detectable en pacientes con infeccion de hepatitis c cronica. |
WO1999023104A2 (en) | 1997-10-30 | 1999-05-14 | The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services | Antitumour uridine analogues |
EA200700564A1 (ru) * | 1998-02-25 | 2007-08-31 | Эмори Юниверсити | 2`-фторнуклеозиды |
WO1999045016A2 (en) | 1998-03-06 | 1999-09-10 | Metabasis Therapeutics, Inc. | Novel prodrugs for phosphorus-containing compounds |
US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
KR100389853B1 (ko) * | 1998-03-06 | 2003-08-19 | 삼성전자주식회사 | 카타로그정보의기록및재생방법 |
GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
TW466112B (en) * | 1998-04-14 | 2001-12-01 | Lilly Co Eli | Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same |
TWI277424B (en) | 1998-05-15 | 2007-04-01 | Schering Corp | Combination therapy for eradicating detectable NCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
US6833361B2 (en) | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
AU767131B2 (en) | 1998-06-08 | 2003-10-30 | F. Hoffmann-La Roche Ag | Use of PEG-IFN-alpha and ribavirin for the treatment of chronic hepatitis C |
DK2415776T3 (en) * | 1998-08-10 | 2016-07-04 | Novartis Ag | Beta-L-2'-deoxy nucleosides for the treatment of Hepatitis B |
US6444652B1 (en) | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
US6277830B1 (en) | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
CA2252144A1 (en) | 1998-10-16 | 2000-04-16 | University Of Alberta | Dual action anticancer prodrugs |
KR100618028B1 (ko) | 1998-11-05 | 2006-08-30 | 쌍트르 나쉬오날 드 라 르쉐르스 쉬앙티피끄 | 항-b형 간염 활성을 가진 뉴클레오시드 |
CA2348948C (en) | 1998-11-05 | 2007-09-18 | Gilles Gosselin | .beta.-l-2'-deoxy-nucleosides for the treatment of hiv infection |
EP1140143A2 (en) | 1998-12-18 | 2001-10-10 | Schering Corporation | Ribavirin-pegylated interferon alfa induction hcv combination therapy |
AU777040B2 (en) | 1999-02-22 | 2004-09-30 | Shire Biochem Inc. | (1,8) naphthyridine derivatives having antiviral activity |
WO2000052015A2 (en) | 1999-03-05 | 2000-09-08 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing prodrugs |
US6831069B2 (en) | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
AU7361400A (en) | 1999-09-08 | 2001-04-10 | Metabasis Therapeutics, Inc. | Prodrugs for liver specific drug delivery |
US6566365B1 (en) | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
CN1740182A (zh) | 1999-12-22 | 2006-03-01 | 症变治疗公司 | 新的双氨基化膦酸酯前药 |
AU2338101A (en) | 1999-12-30 | 2001-07-16 | Biochem Pharma Inc. | Imidazopyrimidine nucleoside analogues with anti-hiv activity |
US7056895B2 (en) * | 2000-02-15 | 2006-06-06 | Valeant Pharmaceuticals International | Tirazole nucleoside analogs and methods for using same |
US6455508B1 (en) | 2000-02-15 | 2002-09-24 | Kanda S. Ramasamy | Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides |
US6495677B1 (en) | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
JP2003523978A (ja) | 2000-02-18 | 2003-08-12 | シャイアー・バイオケム・インコーポレイテッド | ヌクレオシドアナログを用いるflavivirus感染の処置もしくは予防するための方法 |
JP2003532643A (ja) | 2000-04-13 | 2003-11-05 | フアーマセツト・リミテツド | 肝炎ウイルス感染症を治療するための3’−または2’−ヒドロキシメチル置換ヌクレオシド誘導体 |
GB0009486D0 (en) | 2000-04-17 | 2000-06-07 | Univ Cardiff | Chemical compounds |
US6924270B2 (en) * | 2000-04-20 | 2005-08-02 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
GB0011203D0 (en) | 2000-05-09 | 2000-06-28 | Univ Cardiff | Chemical compounds |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
US6787526B1 (en) | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
KR100854398B1 (ko) | 2000-05-26 | 2008-08-26 | 이데닉스 (케이만) 리미티드 | 베타-l-2'-데옥시-뉴클레오사이드를 이용한 델타형 간염바이러스 감염의 치료방법 |
KR20030036189A (ko) * | 2000-05-26 | 2003-05-09 | 이데닉스(케이만)리미티드 | 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물 |
US6875751B2 (en) * | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
MY141594A (en) | 2000-06-15 | 2010-05-14 | Novirio Pharmaceuticals Ltd | 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES |
US6815542B2 (en) * | 2000-06-16 | 2004-11-09 | Ribapharm, Inc. | Nucleoside compounds and uses thereof |
UA72612C2 (en) | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
AU2001286959B2 (en) | 2000-09-01 | 2007-09-06 | Ribozyme Pharmaceuticals, Incorporated | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives |
WO2002032414A2 (en) | 2000-10-18 | 2002-04-25 | Schering Corporation | Ribavirin-pegylated interferon alfa hcv combination therapy |
PT1411954E (pt) | 2000-10-18 | 2011-03-16 | Pharmasset Inc | Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal |
EP2180064A3 (en) * | 2000-10-18 | 2010-08-11 | Pharmasset, Inc. | Multiplex quantification of nucleic acids in diseased cells |
EP1366055A2 (en) | 2000-12-15 | 2003-12-03 | Pharmasset Limited | Antiviral agents for treatment of flaviviridae infections |
CN1267446C (zh) * | 2001-01-22 | 2006-08-02 | 默克公司 | 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物 |
US7105499B2 (en) * | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
IL157478A0 (en) | 2001-03-01 | 2004-03-28 | Pharmasset Ltd | Method for the synthesis of 2', 3'-didehydronucleosides |
GB0112617D0 (en) | 2001-05-23 | 2001-07-18 | Hoffmann La Roche | Antiviral nucleoside derivatives |
GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
EP1478322A4 (en) | 2001-06-22 | 2007-08-08 | Pharmasset Ltd | Beta 2'-OR 3'-HALONUCLEOSIDE |
ES2395463T3 (es) * | 2001-07-16 | 2013-02-15 | Genzyme Corporation | Un inhibidor de N-acilesfingosina glucosiltransferasa |
DE10137252A1 (de) * | 2001-07-31 | 2003-02-13 | Voith Paper Patent Gmbh | Verfahren zum Aufwickeln einer laufenden Materialbahn sowie Wickelmaschine zur Durchführung des Verfahrens |
TWI239270B (en) * | 2001-08-02 | 2005-09-11 | Primax Electronics Ltd | Shredder which can shred small object |
WO2003024461A1 (en) * | 2001-09-20 | 2003-03-27 | Schering Corporation | Hcv combination therapy |
WO2003026675A1 (en) | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
WO2003026589A2 (en) | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
AU2002351077A1 (en) | 2001-11-05 | 2003-05-19 | Exiqon A/S | Oligonucleotides modified with novel alpha-l-rna analogues |
KR100978904B1 (ko) | 2001-12-14 | 2010-08-31 | 파마셋 인코포레이티드 | 바이러스 감염 치료용 n4-아실사이토신 뉴클레오사이드 |
AU2002353165A1 (en) | 2001-12-17 | 2003-06-30 | Ribapharm Inc. | Deazapurine nucleoside libraries and compounds |
WO2003062256A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
WO2003061385A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | Tricyclic nucleoside library compounds, synthesis, and use as antiviral agents |
EP1572705A2 (en) | 2002-01-17 | 2005-09-14 | Ribapharm, Inc. | Sugar modified nucleosides as viral replication inhibitors |
AU2003209045B2 (en) | 2002-02-13 | 2006-12-14 | Isis Pharmaceuticals, Inc. | Methods of inhibiting orthopoxvirus replication with nucleoside compounds |
MXPA04007876A (es) | 2002-02-14 | 2005-06-20 | Pharmasset Ltd | Analogos de nucleosido fluorado modificados. |
RU2004128943A (ru) | 2002-02-28 | 2005-04-20 | Байота, Инк. (Us) | Средства, имитирующие нуклеотиды, и их пролекарственные формы |
US7247621B2 (en) * | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
KR20050006221A (ko) | 2002-05-06 | 2005-01-15 | 제네랩스 테크놀로지스, 인코포레이티드 | C형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체 |
WO2003100017A2 (en) | 2002-05-24 | 2003-12-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
US20040014957A1 (en) | 2002-05-24 | 2004-01-22 | Anne Eldrup | Oligonucleotides having modified nucleoside units |
DE10226932A1 (de) | 2002-06-17 | 2003-12-24 | Bayer Ag | Strahlenhärtende Beschichtungsmittel |
JP2005533777A (ja) | 2002-06-17 | 2005-11-10 | メルク エンド カムパニー インコーポレーテッド | Rna抗ウイルス剤としての炭素環ヌクレオシドアナログ |
CA2488534A1 (en) | 2002-06-21 | 2003-12-31 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
US20060234962A1 (en) | 2002-06-27 | 2006-10-19 | Olsen David B | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
DE14169110T1 (de) | 2002-06-28 | 2022-05-12 | Centre National De La Recherche Scientifique -Cnrs- | Modifizierte 2'- und 3'-Nukleosid-Prodrugs zur Behandlung von Flaviridae-Infektionen |
CN101172993A (zh) | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2′-c-甲基-3′-o-l-缬氨酸酯核糖呋喃基胞苷 |
RS114104A (en) | 2002-06-28 | 2007-02-05 | Idenix (Cayman) Limited, | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |
AU2003248748A1 (en) * | 2002-06-28 | 2004-01-19 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
US20060264389A1 (en) | 2002-07-16 | 2006-11-23 | Balkrishen Bhat | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
AU2003256619A1 (en) | 2002-07-24 | 2004-02-09 | Isis Pharmaceuticals, Inc. | Pyrrolopyrimidine thionucleoside analogs as antivirals |
US20040067877A1 (en) | 2002-08-01 | 2004-04-08 | Schinazi Raymond F. | 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections |
AU2003261659A1 (en) | 2002-09-16 | 2004-04-30 | Kyeong Ho Kim | Decoration band |
US7094768B2 (en) * | 2002-09-30 | 2006-08-22 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
MXPA05003400A (es) * | 2002-09-30 | 2005-06-22 | Genelabs Tech Inc | Derivados de nucleosidos para tratar la infeccion por el virus de la hepatitis c. |
US20040229840A1 (en) | 2002-10-29 | 2004-11-18 | Balkrishen Bhat | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US7265096B2 (en) | 2002-11-04 | 2007-09-04 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
AU2003291755A1 (en) | 2002-11-05 | 2004-06-07 | Isis Pharmaceuticals, Inc. | Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use |
AU2003291682A1 (en) | 2002-11-05 | 2004-06-03 | Isis Pharmaceuticals, Inc. | 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
KR20050088079A (ko) | 2002-11-15 | 2005-09-01 | 이데닉스 (케이만) 리미티드 | 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이 |
TWI332507B (en) | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
EP2319853B1 (en) * | 2002-12-12 | 2014-03-12 | IDENIX Pharmaceuticals, Inc. | Process for the production of 2'-branched nucleosides |
RU2005123395A (ru) | 2002-12-23 | 2006-01-27 | Айденикс (Кайман) Лимитед (Ky) | Способ получения 3-нуклеозидных пролекарств |
WO2004065398A2 (en) | 2003-01-15 | 2004-08-05 | Ribapharm Inc. | Synthesis and use of 2'-substituted-n6-modified nucleosides |
AR043006A1 (es) | 2003-02-12 | 2005-07-13 | Merck & Co Inc | Proceso para preparar ribonucleosidos ramificados |
AU2003225705A1 (en) | 2003-03-07 | 2004-09-30 | Ribapharm Inc. | Cytidine analogs and methods of use |
WO2004084453A2 (en) | 2003-03-20 | 2004-09-30 | Microbiologica Quimica E Farmaceutica Ltd. | METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES |
RU2005133093A (ru) | 2003-03-28 | 2006-07-27 | Фармассет, Инк. (Us) | Соединения для лечения флавивирусных инфекций |
CA2523083C (en) | 2003-04-25 | 2014-07-08 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
KR20060015542A (ko) | 2003-04-28 | 2006-02-17 | 이데닉스 (케이만) 리미티드 | 산업 규모의 뉴클레오시드 합성 |
US20040259934A1 (en) | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
EP1656093A2 (en) | 2003-05-14 | 2006-05-17 | Idenix (Cayman) Limited | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses |
WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
US7429572B2 (en) | 2003-05-30 | 2008-09-30 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
EP1644395B1 (en) * | 2003-06-19 | 2006-11-22 | F. Hoffmann-La Roche Ag | Processes for preparing 4'azido nucleoside derivatives |
GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
CA2537114C (en) | 2003-08-27 | 2012-10-02 | Biota, Inc. | Tricyclic nucleosides or nucleotides as therapeutic agents |
AU2004275770A1 (en) | 2003-09-22 | 2005-04-07 | Acidophil Llc | Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
US7144868B2 (en) * | 2003-10-27 | 2006-12-05 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
US20050137141A1 (en) * | 2003-10-24 | 2005-06-23 | John Hilfinger | Prodrug composition |
NZ546201A (en) * | 2003-10-27 | 2009-05-31 | Genelabs Tech Inc | Nucleoside compounds for treating viral infections |
US7157434B2 (en) | 2003-10-27 | 2007-01-02 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
GB0401088D0 (en) | 2004-01-19 | 2004-02-18 | Univ Cardiff | Phosphoramidate derivatives |
WO2006016930A2 (en) | 2004-05-14 | 2006-02-16 | Intermune, Inc. | Methods for treating hcv infection |
AU2005254057B2 (en) | 2004-06-15 | 2011-02-17 | Isis Pharmaceuticals, Inc. | C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase |
US7560434B2 (en) | 2004-06-22 | 2009-07-14 | Biocryst Pharmaceuticals, Inc. | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
BRPI0512360A (pt) | 2004-06-23 | 2008-03-11 | Idenix Cayman Ltd | derivados de 5-aza-7-deazapurina para o tratamento de flaviviridae |
CA2571079A1 (en) | 2004-06-24 | 2006-02-02 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
CN101023094B (zh) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
RU2407747C2 (ru) | 2004-07-21 | 2010-12-27 | Фармассет, Инк. | Способ получения алкилзамещенных 2-дезокси-2-фтор-d-рибофуранозил-пиримидинов и пуринов и их производных |
PT1778251E (pt) | 2004-07-27 | 2011-06-29 | Gilead Sciences Inc | Análogos de fosfonato de compostos inibidores de vih |
CA2577526A1 (en) * | 2004-08-23 | 2006-03-02 | Joseph Armstrong Martin | Antiviral 4'-azido-nucleosides |
AU2005289517A1 (en) | 2004-09-24 | 2006-04-06 | Centre National De La Recherche Scientifique | Methods and compositions for treating flaviviruses, pestiviruses and hepacivirus |
CA2583351A1 (en) | 2004-10-06 | 2006-04-13 | Migenix Inc. | Combination anti-viral compositions comprising castanospermine and methods of use |
US20080280842A1 (en) | 2004-10-21 | 2008-11-13 | Merck & Co., Inc. | Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection |
WO2006121468A1 (en) * | 2004-11-22 | 2006-11-16 | Genelabs Technologies, Inc. | 5-nitro-nucleoside compounds for treating viral infections |
WO2006063149A1 (en) | 2004-12-09 | 2006-06-15 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
WO2006063717A2 (en) | 2004-12-16 | 2006-06-22 | Febit Biotech Gmbh | Polymerase-independent analysis of the sequence of polynucleotides |
CA2597213A1 (en) | 2005-02-09 | 2006-09-14 | Migenix Inc. | Compositions and methods for treating or preventing flaviviridae infections |
US20100279974A1 (en) | 2005-03-09 | 2010-11-04 | Claire Pierra | Nucleosides With Non-Natural Bases as Anti-Viral Agents |
WO2006097323A1 (en) | 2005-03-18 | 2006-09-21 | Lutz Weber | TETRAHYDRO-ISOQUINOLIN-l-ONES FOR THE TREATMENT OF CANCER |
DE102005012681A1 (de) | 2005-03-18 | 2006-09-21 | Weber, Lutz, Dr. | Neue 1,5-Dihydro-pyrrol-2-one |
GT200600119A (es) | 2005-03-24 | 2006-10-25 | Composiciones farmaceuticas | |
AR056327A1 (es) | 2005-04-25 | 2007-10-03 | Genelabs Tech Inc | Compuestos de nucleosidos para el tratamiento de infecciones virales |
WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
KR20080003933A (ko) | 2005-05-31 | 2008-01-08 | 노파르티스 아게 | 철이 발병에 관여하는 간질환의 치료 |
CA2615626A1 (en) | 2005-07-18 | 2007-01-25 | Novartis Ag | Small animal model for hcv replication |
CA2618560A1 (en) | 2005-08-09 | 2007-02-22 | Merck & Co., Inc. | Ribonucleoside cyclic acetal derivatives for the treatment of rna-dependent rna viral infection |
US20090118223A1 (en) | 2005-08-12 | 2009-05-07 | Erion Mark D | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives |
AR057096A1 (es) | 2005-08-26 | 2007-11-14 | Chancellors Masters And Schola | Proceso para preparar acidos y lactonas sacarinicos |
EP1937825B1 (en) | 2005-09-26 | 2016-12-21 | Gilead Pharmasset LLC | Modified 4'-nucleosides as antiviral agents |
NZ568909A (en) | 2005-12-09 | 2011-10-28 | Hoffmann La Roche | Antiviral 4-fluoro-4-methyl nucleoside prodrugs |
US7781576B2 (en) | 2005-12-23 | 2010-08-24 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
EP1987050A2 (en) | 2006-02-14 | 2008-11-05 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
US7842672B2 (en) | 2006-07-07 | 2010-11-30 | Gilead Sciences, Inc. | Phosphonate inhibitors of HCV |
SI2084174T1 (sl) | 2006-10-10 | 2013-10-30 | Gilead Pharmasset Llc | Priprava nukleozidov ribofuranozil pririmidinov |
GB0623493D0 (en) | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
CA2672613A1 (en) | 2006-12-20 | 2008-07-03 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection |
US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
US8324179B2 (en) | 2007-02-09 | 2012-12-04 | Gilead Sciences, Inc. | Nucleoside analogs for antiviral treatment |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
CA2685748A1 (en) | 2007-05-14 | 2008-11-14 | Rfs Pharma, Llc. | Azido purine nucleosides for treatment of viral infections |
GB0718575D0 (en) | 2007-09-24 | 2007-10-31 | Angeletti P Ist Richerche Bio | Nucleoside derivatives as inhibitors of viral polymerases |
US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
PT2268642E (pt) | 2008-04-23 | 2015-06-02 | Gilead Sciences Inc | Análogos de carba-nulceósidos 1¿-substituídos para tratamento antiviral |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
GB0815968D0 (en) | 2008-09-03 | 2008-10-08 | Angeletti P Ist Richerche Bio | Antiviral agents |
EA019295B1 (ru) | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Соединения пуриновых нуклеозидов и способ их получения |
US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
EP2376088B1 (en) | 2008-12-23 | 2017-02-22 | Gilead Pharmasset LLC | 6-O-Substituted-2-amino-purine nucleoside phosphoramidates |
GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
CA2751458C (en) | 2009-02-06 | 2018-06-05 | Rfs Pharma, Llc | Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections |
ES2628842T3 (es) | 2009-02-10 | 2017-08-04 | Gilead Sciences, Inc. | Método para la preparación de tieno[3,4-d]pirimidin-7-il ribósidos |
TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US7973013B2 (en) | 2009-09-21 | 2011-07-05 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
US8455451B2 (en) | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
EA201270632A1 (ru) | 2009-11-16 | 2013-01-30 | Юниверсити Оф Джорджия Рисерч Фаундейшн, Инк. | 2'-фтор-6'-метилен карбоциклические нуклеозиды и способы лечения вирусных инфекций |
US8816074B2 (en) | 2009-11-16 | 2014-08-26 | University of Georgia Foundation, Inc. | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections |
PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
JP2013527145A (ja) | 2010-03-31 | 2013-06-27 | ギリード・ファーマセット・エルエルシー | リン含有活性化剤の立体選択的合成 |
US8680071B2 (en) | 2010-04-01 | 2014-03-25 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
WO2011156757A1 (en) | 2010-06-10 | 2011-12-15 | Gilead Sciences, Inc. | Combination of anti-hcv compounds with ribavirin for the treatment of hcv |
KR101995598B1 (ko) | 2010-07-19 | 2019-07-02 | 길리애드 사이언시즈, 인코포레이티드 | 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법 |
TW201305185A (zh) | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之2’-氟取代之碳-核苷類似物 |
AR084044A1 (es) | 2010-11-30 | 2013-04-17 | Pharmasset Inc | Compuestos 2’-espiro-nucleosidos |
WO2012087596A1 (en) | 2010-12-20 | 2012-06-28 | Gilead Sciences, Inc. | Combinations for treating hcv |
EP2658857B1 (en) | 2010-12-29 | 2016-11-02 | Inhibitex, Inc. | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections |
CN103403014B (zh) | 2011-01-03 | 2016-07-06 | 河南美泰宝生物制药有限公司 | O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途 |
JP2014514295A (ja) | 2011-03-31 | 2014-06-19 | アイディニックス ファーマシューティカルズ インコーポレイテッド | ウイルス感染の治療のための化合物および薬学的組成物 |
WO2012142093A2 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
BR112013026345A2 (pt) | 2011-04-13 | 2019-04-24 | Merck Sharp & Dohe Corp. | composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv |
WO2012142523A2 (en) | 2011-04-13 | 2012-10-18 | Gilead Sciences, Inc. | 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment |
EP2697242B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
CN103687866A (zh) | 2011-05-19 | 2014-03-26 | Rfs制药公司 | 用于治疗病毒性感染的嘌呤单磷酸酯前药 |
EP2755983B1 (en) | 2011-09-12 | 2017-03-15 | Idenix Pharmaceuticals LLC. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
JP2014526474A (ja) * | 2011-09-12 | 2014-10-06 | アイディニックス ファーマシューティカルズ インコーポレイテッド | ウイルス感染の治療のための化合物および薬学的組成物 |
US8575119B2 (en) | 2011-09-23 | 2013-11-05 | Enanta Pharmaceuticals, Inc. | 2′-chloroacetylenyl substituted nucleoside derivatives |
EP2768838A1 (en) | 2011-10-14 | 2014-08-27 | IDENIX Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
SG11201407674TA (en) | 2012-05-22 | 2014-12-30 | Idenix Pharmaceuticals Inc | D-amino acid compounds for liver disease |
EP2852605B1 (en) | 2012-05-22 | 2018-01-31 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphate prodrugs for hcv infection |
WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
TR201809048T4 (tr) | 2012-10-08 | 2018-07-23 | Centre Nat Rech Scient | Hcv enfeksiyonu için 2'-kloro nükleosit analogları. |
WO2014059902A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | 2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases |
AR092959A1 (es) | 2012-10-17 | 2015-05-06 | Merck Sharp & Dohme | Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales |
US9242988B2 (en) | 2012-10-17 | 2016-01-26 | Merck Sharp & Dohme Corp. | 2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
US20140112886A1 (en) | 2012-10-19 | 2014-04-24 | Idenix Pharmaceuticals, Inc. | Dinucleotide compounds for hcv infection |
US10723754B2 (en) | 2012-10-22 | 2020-07-28 | Idenix Pharmaceuticals Llc | 2′,4′-bridged nucleosides for HCV infection |
WO2014078436A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of sp-nucleoside analog |
EP2920195A1 (en) | 2012-11-14 | 2015-09-23 | IDENIX Pharmaceuticals, Inc. | D-alanine ester of rp-nucleoside analog |
US20140205566A1 (en) | 2012-11-30 | 2014-07-24 | Novartis Ag | Cyclic nucleuoside derivatives and uses thereof |
WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
EP2970358B1 (en) * | 2013-03-04 | 2021-06-30 | Idenix Pharmaceuticals LLC | 3'-deoxy nucleosides for the treatment of hcv |
EP2970357A1 (en) | 2013-03-13 | 2016-01-20 | IDENIX Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
US9187515B2 (en) | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
WO2014197578A1 (en) | 2013-06-05 | 2014-12-11 | Idenix Pharmaceuticals, Inc. | 1',4'-thio nucleosides for the treatment of hcv |
EP3010512B1 (en) | 2013-06-18 | 2017-12-27 | Merck Sharp & Dohme Corp. | Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
US20150037282A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
-
2001
- 2001-05-22 MY MYPI20012400A patent/MY164523A/en unknown
- 2001-05-23 AP APAP/P/2002/002704A patent/AP1782A/en active
- 2001-05-23 CZ CZ20024149A patent/CZ301169B6/cs not_active IP Right Cessation
- 2001-05-23 PE PE2001000470A patent/PE20020206A1/es not_active Application Discontinuation
- 2001-05-23 RS YU92102A patent/RS52394B/en unknown
- 2001-05-23 CA CA2712547A patent/CA2712547A1/en not_active Abandoned
- 2001-05-23 SG SG10201710373RA patent/SG10201710373RA/en unknown
- 2001-05-23 CN CNB018132332A patent/CN100402545C/zh not_active Expired - Lifetime
- 2001-05-23 MX MXPA02011635A patent/MXPA02011635A/es active IP Right Grant
- 2001-05-23 KR KR1020087003747A patent/KR20080030670A/ko active Search and Examination
- 2001-05-23 CA CA2409613A patent/CA2409613C/en not_active Expired - Lifetime
- 2001-05-23 SG SG200407754-1A patent/SG156517A1/en unknown
- 2001-05-23 CN CNA2008101081405A patent/CN101469009A/zh active Pending
- 2001-05-23 AU AU2001274906A patent/AU2001274906B2/en not_active Expired
- 2001-05-23 JP JP2001586308A patent/JP2004533401A/ja not_active Withdrawn
- 2001-05-23 IL IL15293401A patent/IL152934A0/xx unknown
- 2001-05-23 UY UY26724A patent/UY26724A1/es not_active IP Right Cessation
- 2001-05-23 PL PL389775A patent/PL227118B1/pl unknown
- 2001-05-23 EP EP06075216A patent/EP1669364A3/en not_active Withdrawn
- 2001-05-23 PE PE2010000216A patent/PE20100363A1/es not_active Application Discontinuation
- 2001-05-23 AU AU7490601A patent/AU7490601A/xx active Pending
- 2001-05-23 PL PL409123A patent/PL409123A1/pl unknown
- 2001-05-23 WO PCT/US2001/016671 patent/WO2001090121A2/en active Application Filing
- 2001-05-23 EP EP10183341.6A patent/EP2319856B1/en not_active Expired - Lifetime
- 2001-05-23 AP AP2006003817A patent/AP2006003817A0/xx unknown
- 2001-05-23 KR KR1020027015790A patent/KR20030036188A/ko not_active Application Discontinuation
- 2001-05-23 ES ES01941564.5T patent/ES2620807T3/es not_active Expired - Lifetime
- 2001-05-23 AR ARP010102458A patent/AR035336A1/es not_active Application Discontinuation
- 2001-05-23 EA EA200201279A patent/EA007178B1/ru not_active IP Right Cessation
- 2001-05-23 EA EA200600582A patent/EA011720B1/ru not_active IP Right Cessation
- 2001-05-23 RS RS20120201A patent/RS53722B1/en unknown
- 2001-05-23 SG SG2008069635A patent/SG189556A1/en unknown
- 2001-05-23 TW TW096112264A patent/TW200730537A/zh unknown
- 2001-05-23 NZ NZ522863A patent/NZ522863A/en not_active IP Right Cessation
- 2001-05-23 CN CNA2008101081373A patent/CN101367856A/zh active Pending
- 2001-05-23 BR BR0111127-2A patent/BR0111127A/pt not_active Application Discontinuation
- 2001-05-23 PL PL366159A patent/PL220775B1/pl not_active IP Right Cessation
- 2001-05-23 EP EP01941564.5A patent/EP1292603B8/en not_active Expired - Lifetime
- 2001-05-23 SG SG2013055223A patent/SG193778A1/en unknown
- 2001-05-23 SG SG2010004232A patent/SG192287A1/en unknown
- 2001-05-23 NZ NZ540755A patent/NZ540755A/en not_active IP Right Cessation
- 2001-05-23 TW TW090112342A patent/TWI317735B/zh not_active IP Right Cessation
- 2001-05-23 TW TW094131057A patent/TWI331528B/zh not_active IP Right Cessation
- 2001-05-23 KR KR1020077006401A patent/KR20070036806A/ko not_active Application Discontinuation
- 2001-05-23 ES ES10183341T patent/ES2531011T3/es not_active Expired - Lifetime
- 2001-05-23 CA CA2910995A patent/CA2910995C/en not_active Expired - Lifetime
- 2001-05-23 TW TW098105775A patent/TWI335334B/zh not_active IP Right Cessation
- 2001-05-23 US US09/864,078 patent/US6914054B2/en not_active Expired - Lifetime
-
2002
- 2002-11-19 IL IL152934A patent/IL152934A/en active IP Right Grant
- 2002-11-22 NO NO20025627A patent/NO325352B1/no not_active IP Right Cessation
- 2002-12-12 ZA ZA200210101A patent/ZA200210101B/en unknown
- 2002-12-16 MA MA26957A patent/MA27292A1/fr unknown
-
2003
- 2003-06-20 US US10/602,976 patent/US7169766B2/en not_active Expired - Lifetime
- 2003-06-20 US US10/602,136 patent/US7157441B2/en not_active Expired - Lifetime
- 2003-06-20 US US10/602,691 patent/US7608597B2/en not_active Expired - Lifetime
- 2003-06-20 US US10/602,142 patent/US20050124532A1/en not_active Abandoned
-
2004
- 2004-06-01 ZA ZA200404305A patent/ZA200404305B/en unknown
-
2006
- 2006-07-21 AU AU2006203121A patent/AU2006203121B2/en not_active Expired
- 2006-07-21 AU AU2006203122A patent/AU2006203122B2/en not_active Expired
-
2007
- 2007-06-20 NO NO20073151A patent/NO332750B1/no not_active IP Right Cessation
-
2008
- 2008-12-31 IL IL196301A patent/IL196301A0/en active IP Right Grant
-
2009
- 2009-07-16 US US12/504,601 patent/US8299038B2/en not_active Expired - Lifetime
-
2010
- 2010-01-07 AU AU2010200077A patent/AU2010200077B2/en not_active Expired
-
2012
- 2012-09-20 US US13/623,674 patent/US20130017171A1/en not_active Abandoned
- 2012-10-10 NO NO20121146A patent/NO20121146L/no unknown
- 2012-12-28 US US13/730,669 patent/US10363265B2/en not_active Expired - Fee Related
-
2013
- 2013-02-27 JP JP2013036937A patent/JP5926211B2/ja not_active Expired - Lifetime
- 2013-07-29 US US13/953,687 patent/US20130315862A1/en not_active Abandoned
- 2013-10-10 JP JP2013212565A patent/JP5753563B2/ja not_active Expired - Lifetime
-
2014
- 2014-04-22 UY UY0001035542A patent/UY35542A/es not_active Application Discontinuation
-
2016
- 2016-03-28 JP JP2016063156A patent/JP6240699B2/ja not_active Expired - Lifetime
-
2017
- 2017-07-28 JP JP2017146982A patent/JP2018012702A/ja active Pending
-
2018
- 2018-12-12 JP JP2018232209A patent/JP2019069968A/ja not_active Withdrawn
-
2019
- 2019-06-13 US US16/440,659 patent/US10758557B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP2006003817A0 (en) | methods and compositions for treating hepatitis C virus | |
EP1435974A4 (en) | METHOD AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS WITH 4'-MODIFIED NUCLEOSIDES | |
HK1145435A1 (en) | Composition and method for treating cancer using herpes virus | |
AP2006003708A0 (en) | Methods and compositions for treating flavivirusesand pestiviruses | |
IL144517A0 (en) | Compositions and methods for treating cataracts | |
GB0021281D0 (en) | Software virus protection | |
HK1097413A1 (en) | Compositions comprising viruses and methods for concentrating virus preparations | |
EP1322325A4 (en) | INHIBITION OF PROCESSING AND REPLICATION OF HEPATITIS C VIRUS | |
AU2002346686A1 (en) | Compositions and method for treating hepatitis virus infection | |
GB0017720D0 (en) | Modified virus | |
EP1351647A4 (en) | COMPOSITIONS AND METHODS FOR TREATING HYPERPIGMENTATION | |
IL157251A0 (en) | Hepatitis b virus treatment | |
EP1326625A4 (en) | IMMUNOGENIC COMPOSITION OF HEPATITIS C AND METHODS OF USING THE SAME | |
EP1068362A4 (en) | HEPATITIS C VIRUS NS5B COMPOSITIONS AND METHOD FOR THEIR USE | |
EP1253930A4 (en) | METHODS AND COMPOSITIONS FOR TREATING HEPATOCELLULAR CANCER | |
IL149314A0 (en) | Agent for treating hepatitis c | |
AU2001234596A1 (en) | Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections | |
AU2003254129A8 (en) | Method and composition for treating and preventing hepatitis b infection and symptoms thereof | |
AU2003256678A8 (en) | Method and composition for treating and preventing hepatitis c infection | |
EP1290230A4 (en) | HEPATITIS C VIRUS CONJUGATE | |
HUP0600449A2 (en) | Methods of treating liver fibrosis and hepatitis c virus infection | |
AU2002342188A8 (en) | Methods and compositions for treating flavivirus-mediated disease | |
EP1305017A4 (en) | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF SYNDROME X | |
EP1311709A4 (en) | METHODS AND COMPOSITIONS FOR DIRECTED MOLECULAR EVOLUTION USING MODIFICATION OF THE END OF DNA | |
AU2003299493A8 (en) | Compositions and methods for the treatment of hepatitis c virus infection |